Zydus Lifesciences informs about press release

25 Oct 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 25, 2023 titled ‘Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)’.

The above information is a part of company’s filings submitted to BSE.


Zydus Lifesciences Share Price

910.00 5.15 (0.57%)
16-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.75
Dr. Reddys Lab 1269.30
Cipla 1355.80
Zydus Lifesciences 910.00
Lupin 2220.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×